• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Cantor Fitzgerald initiated coverage on NewAmsterdam Pharma with a new price target

    6/4/25 7:45:30 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NAMS alert in real time by email
    Cantor Fitzgerald initiated coverage of NewAmsterdam Pharma with a rating of Overweight and set a new price target of $42.00
    Get the next $NAMS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NAMS

    DatePrice TargetRatingAnalyst
    6/17/2025$42.00Buy
    Citigroup
    6/10/2025$44.00Buy
    Stifel
    6/4/2025$42.00Overweight
    Cantor Fitzgerald
    12/30/2024$48.00Buy
    H.C. Wainwright
    5/15/2024Buy
    TD Cowen
    3/14/2024$35.00Sector Outperform
    Scotiabank
    1/18/2024$30.00Buy
    Guggenheim
    1/16/2024$37.00Overweight
    Piper Sandler
    More analyst ratings

    $NAMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on NewAmsterdam Pharma with a new price target

      Citigroup initiated coverage of NewAmsterdam Pharma with a rating of Buy and set a new price target of $42.00

      6/17/25 7:50:10 AM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on NewAmsterdam Pharma with a new price target

      Stifel initiated coverage of NewAmsterdam Pharma with a rating of Buy and set a new price target of $44.00

      6/10/25 8:09:06 AM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on NewAmsterdam Pharma with a new price target

      Cantor Fitzgerald initiated coverage of NewAmsterdam Pharma with a rating of Overweight and set a new price target of $42.00

      6/4/25 7:45:30 AM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care